These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 2338325

  • 1. [Lipid therapy with etofibrate. Reduction of multiple risk factors with an active substance. Report of an international seminar. 8-11 November 1989, Houston, Texas].
    Fortschr Med Suppl; 1990; 85():1-15. PubMed ID: 2338325
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
    Słowińska R, Bochenek W, Unlot J.
    Pol Tyg Lek; 1983 Apr 25; 38(17):529-32. PubMed ID: 6356087
    [No Abstract] [Full Text] [Related]

  • 4. [Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
    Schatton W, Holm E.
    Fortschr Med; 1986 Apr 03; 104(13):280-2. PubMed ID: 3699655
    [No Abstract] [Full Text] [Related]

  • 5. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K, Djaja S, Richter E.
    Ther Ggw; 1982 May 03; 121(5):301-11. PubMed ID: 6953613
    [No Abstract] [Full Text] [Related]

  • 6. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
    Altomonte L, Mingrone G, Negrini A, De Cunto F, Greco AV.
    Clin Ter; 1981 Jan 15; 96(1):31-8. PubMed ID: 7016409
    [No Abstract] [Full Text] [Related]

  • 7. [Atherosclerosis treatment with etofibrate retard. New perspectives].
    Degenring FH, Schatton W, Hotz W.
    Fortschr Med; 1983 Aug 11; 101(30):1391-6. PubMed ID: 6618402
    [Abstract] [Full Text] [Related]

  • 8. [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
    Füsgen I, Summa JD.
    Med Klin; 1980 Nov 07; 75(23):823-5. PubMed ID: 7442597
    [Abstract] [Full Text] [Related]

  • 9. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L, Mingrone G, Ghirlanda G, Manna R, Rebuzzi A, Pala MA, Greco AV.
    Minerva Med; 1980 Feb 11; 71(4):273-8. PubMed ID: 7354946
    [Abstract] [Full Text] [Related]

  • 10. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
    Horváth M, Varsányl M, Jovanovich N, Romics L, Gerö S.
    Allergol Immunopathol (Madr); 1990 Feb 11; 18(2):95-9. PubMed ID: 2371944
    [Abstract] [Full Text] [Related]

  • 11. [Plafibride--is it an effective drug as a hypolipemic agent?].
    Joven J.
    Med Clin (Barc); 1985 Apr 20; 84(15):632. PubMed ID: 3999857
    [No Abstract] [Full Text] [Related]

  • 12. [Therapy of vascular insufficiency of the legs with plafibride].
    Lázaro Campillo T, Gesto Castromil R, de la Sierra L, Pujadas J, Villafana W, Moreno R.
    Med Clin (Barc); 1984 Dec 01; 83(18):752-5. PubMed ID: 6521538
    [No Abstract] [Full Text] [Related]

  • 13. [Therapy of ischemic ulcers of the lower extremities using plafibride].
    Palou Monzo J, López-Delmás FJ.
    Angiologia; 1984 Dec 01; 36(6):273-8. PubMed ID: 6517385
    [No Abstract] [Full Text] [Related]

  • 14. [Therapeutic effects of bezafibrate in hyperlipidemia].
    Kunesová M, Honková M, Zeman M, Mares P, Skorepa J.
    Cas Lek Cesk; 1983 May 20; 122(20):628-31. PubMed ID: 6342789
    [No Abstract] [Full Text] [Related]

  • 15. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M, Nowicka G, Szostak WB, Kłosiewicz-Latoszek L.
    Kardiol Pol; 1982 May 20; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract] [Full Text] [Related]

  • 16. [Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
    Janka HU, Standl A, Holler HD, Mehnert H.
    MMW Munch Med Wochenschr; 1982 May 28; 124(21):535-7. PubMed ID: 6810123
    [No Abstract] [Full Text] [Related]

  • 17. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J, Vinzia C, Gómez JM, Morató J.
    Med Clin (Barc); 1984 May 19; 82(19):840-2. PubMed ID: 6738212
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [What is important in therapy of hyperlipoproteinemia. Lipo-Merz retard (etofibrate) lowers the atherogenic index].
    Fortschr Med; 1982 Sep 16; 100(35):1622-3. PubMed ID: 7173769
    [No Abstract] [Full Text] [Related]

  • 20. [Stability of antilipidemic etofibrate and its metabolites towards gastrointestinal and blood hydrolases (author's transl)].
    Oelschläger H, Rothley D, Ewert M, Nachev P.
    Arzneimittelforschung; 1980 Sep 16; 30(6):984-8. PubMed ID: 7191278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.